Related Experiment Video

Updated: Sep 10, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K

miRNAs in Pulmonary Hypertension: Mechanistic Insights and Therapeutic Potential

Jindong Fang1,2,3, Hongyang Chen1,2,3, Zhuangzhuang Jia1,2,3

  • 1School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming 650500, China.

Biomedicines
|August 28, 2025
PubMed

Insights

MicroRNAs (miRNAs) show potential in regulating pulmonary hypertension (PH) pathogenesis, acting as biomarkers and therapeutic agents. Further research is needed to translate these findings into clinical applications for PH.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Cardiovascular research

Background:

  • Pulmonary hypertension (PH) is a severe vascular disease.
  • Key pathogenic mechanisms include vascular remodeling, metabolic reprogramming, inflammation, and fibrosis.
  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.

Purpose of the Study:

  • To review the role of miRNAs in PH pathogenesis.
  • To explore the potential of miRNAs as biomarkers for PH.
  • To discuss miRNAs as therapeutic agents for PH.

Main Methods:

  • Literature review of studies on miRNAs and PH.
  • Analysis of miRNA regulatory mechanisms in PH.
  • Synthesis of current experimental findings.

Main Results:

  • miRNAs are implicated in the pathogenesis of PH.
  • miRNAs demonstrate potential as diagnostic biomarkers.
  • miRNAs offer prospects for novel therapeutic strategies.

Conclusions:

  • miRNAs play a significant regulatory role in PH.
  • Translating miRNA research into clinical practice requires further investigation.
  • Future applications of miRNAs in PH diagnosis and treatment are promising.
Keywords:
Pulmonary hypertensionmetabolic reprogrammingmicroRNAright ventricular dysfunctionvascular remodeling

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

368

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
284
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251